Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 75 /hr

★★★★★

☆☆☆☆☆

Hire Angelo M.

United States

USD 75 /hr

Clinical Biostatistician | R & SAS | Statistical Analysis | Clinical Research

Profile Summary

Need a statistician who can do more than simply run a model? I’m a Clinical Biostatistician with an MPH in Biostatistics & Bioinformatics from Emory University, with professional experience in clinical research, oncology, biomedical data analysis, statistical programming, and data visualization. I specialize in turning complex datasets and research questions into rigorous statistical analyses, publication-quality figures, and clear, actionable conclusions. What I can help with: Statistical Analysis • Kaplan-Meier & survival analysis • Cox proportional hazards regression • Logistic & linear regression • Generalized linear models • Mixed-effects / longitudinal models • Nonparametric & robust methods • Predictive modeling • Agreement & concordance analysis • Clinical endpoint analysis • Biomarker & minimal residual disease (MRD) research R & SAS Programming • Data cleaning and preparation • Statistical programming • Data manipulation and restructuring • Reproducible analysis workflows • Debugging and improving existing code • R ↔ SAS analysis validation I have extensive experience using R and SAS to transform raw clinical/research data into reproducible analyses. In R, I regularly work with tools including ggplot2, dplyr, tidyr, survival, survminer, and ggsurvfit. Data Visualization I create professional, publication- and presentation-ready visualizations including Kaplan-Meier curves, forest plots, boxplots, scatterplots, Bland-Altman plots, agreement plots, heatmaps, and custom scientific figures. My approach I don't believe statistical consulting is simply about knowing which function to run. A strong analysis starts with understanding the research question. My workflow is: Understand the question → Prepare the data → Select the appropriate method → Perform & validate the analysis → Visualize the results → Clearly communicate the conclusion. Whether you need help with a one-time statistical analysis, R/SAS programming, clinical research project, data visualization, or ongoing biostatistical support, I can help take your project from raw data to a polished final result. If you have a dataset, research question, or statistical problem you're working through, send me the details and let's figure out the best way to approach it.

Subject Matter Expertise

• ☆ Biostatistics
• ☆ Data Analysis
• ☆ Data Visualization
• ☆ Statistics
• ☆ Health Data Analysis
• ☆ Bioinformatics
• ☆ SAS
• ☆ R
• ☆ Preclinical Research

Services

• Writing
• Research
• Consulting
• Data & AI

Writing Clinical Trial Documentation, Medical Writing, Non-Medical Regulatory Writing, Technical Writing, Business & Legal Writing, Copywriting, Creative Writing

Research Market Research, User Research, Technology Scouting

Consulting Healthcare Consulting, Scientific and Technical Consulting

Data & AI Predictive Modeling, Statistical Analysis, Algorithm Design-Non ML, Algorithm Design-ML, Data Visualization, Big Data Analytics, Data Cleaning, Data Processing, Data Insights

Work Experience

Clinical Biostatistician II

Abbott

August 2026 - Present

Biostatistician

Winship Cancer Institute

June 2023 - August 2026

Education

M.S.

Emory University

August 2021 - May 2023

BS

University of Illinois at Urbana-Champaign

August 2017 - May 2021

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Angelo Marra, Margo B Gerke, Michelle Jayaraj, Ahmet Yildrim, Akshay Bedmutha, Jacqueline T Brown, Bassel Nazha, Jacob E Berchuck, Ravi Bharat Parikh, Shahid Ahmed, et al. (2026). Novel risk scoring system for patients with metastatic castration-resistant prostate cancer treated with lutetium-177–PSMA-617 . The Oncologist.

Margo B. Gerke, Yuan Liu, Akshay Bedmutha, Jacqueline T. Brown, Bassel Nazha, Jacob E. Berchuck, Ravi Bharat Parikh, Shahid Ahmed, Jordan Alana Ciuro, et al., Angelo Marra (2026). Inflammatory biomarkers have a prognostic role in patients with metastatic castration‐resistant prostate cancer treated with Lutetium‐177–PSMA‐617 . Cancer.

Angelo Marra, Margo Brooke Gerke, Akshay Bedmutha, Yuan Liu, Jacqueline T Brown, Bassel Nazha, Jacob E Berchuck, Ravi Bharat Parikh, Shahid Ahmed, Jordan Alana Ciuro, et al. (2026). Clinical outcomes of lutetium-177–PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer . The Oncologist.

Angelo Marra, Yijian Fan, Rui Jin, Lenore Monterroza, Xiuju Liu, Chunzi Huang, Xiulei Mo, Haian Fu, Melissa Gilbert-Ross, Adam I Marcus, et al. (2025). Suppression of LKB1-mutant lung adenocarcinoma by natural killer cells from females . JNCI: Journal of the National Cancer Institute.

Angelo Marra, Nabil F. Saba, Ritu Chaudhary, Kedar Kirtane, Asari Ekpenyong, Ashley McCook-Veal, Nicole C. Schmitt, Jennifer H. Gross, Mihir R. Patel, Jill Remick, et al. (2024). Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis . Clinical Cancer Research.

PREPRINT

Angelo Marra, Nabil F. Saba, Ritu Chaudhary, Kedar Kirtane, Asari Ekpenyong, Ashley McCook-Veal, Nicole C. Schmitt, Jennifer H. Gross, Mihir R. Patel, Jill Remick, et al. (2024). Data from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis .

Angelo Marra, Nabil F. Saba, Ritu Chaudhary, Kedar Kirtane, Asari Ekpenyong, Ashley McCook-Veal, Nicole C. Schmitt, Jennifer H. Gross, Mihir R. Patel, Jill Remick, et al. (2024). Supplementary Table S1 from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis .

Angelo Marra, Nabil F. Saba, Ritu Chaudhary, Kedar Kirtane, Asari Ekpenyong, Ashley McCook-Veal, Nicole C. Schmitt, Jennifer H. Gross, Mihir R. Patel, Jill Remick, et al. (2024). Supplementary Table S2 from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis .

Angelo Marra, Nabil F. Saba, Ritu Chaudhary, Kedar Kirtane, Asari Ekpenyong, Ashley McCook-Veal, Nicole C. Schmitt, Jennifer H. Gross, Mihir R. Patel, Jill Remick, et al. (2024). Supplementary Table S3 from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis .